A Phase 1b/2 Study of PEP503 (Radioenhancer) With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer
Phase of Trial: Phase I/II
Latest Information Update: 29 Jun 2017
At a glance
- Drugs NBTXR 3 (Primary) ; Cisplatin
- Indications Head and neck cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors PharmaEngine
- 28 Nov 2016 According to Nanobiotix media release, complete data will be available by second half of 2017.
- 19 Oct 2016 According to PharmaEngine media release, company announced today that the first patient has been dosed in this study.
- 19 Oct 2016 According to PharmaEngine media release, status changed from not yet recruiting to recruiting.